Sign In

Research

Breaking News

Study puts price tag on lost earnings from racial disparities in cancer mortality

$3.2 billion in lost earnings would have been avoided in 2015 alone had mortality and earning been equal among blacks and whites

A new ACS study puts a price tag on racial disparities in cancer mortality, finding that $3.2 billion in lost earnings would have been avoided in 2015 if non-Hispanic (NH) blacks had equal years of life lost from cancer deaths and earning rates as NH whites. The study appears in JNCI Cancer Spectrum.

Little is known about disparities in economic burden due to premature cancer deaths by race/ethnicity in the U.S. To learn more, investigators led by Jingxuan Zhao, MPH, (pictured here), compared person-years of life lost (PYLL) and lost earnings due to premature cancer deaths by race/ethnicity. PYLL was calculated using national cancer death and life expectancy data. That was combined with annual median earnings to generate lost earnings. PYLL and lost earnings were then compared among individuals who died at age 16-84 years due to cancer by racial/ethnic groups: NH white, NH black, NH Asian or Pacific Islander (API), and Hispanic.

They found that in 2015, age-standardized lost earning rates (per 100,000 person-years) were $34.9 million for NH whites, $43.5 million for NH blacks, $22.2 million for APIs, and $24.5 million for Hispanics. NH blacks had higher age-standardized PYLL and lost earning rates than NH whites for 13 out of 19 cancer sites studied.

“If age-specific PYLL and lost earning rates for NH blacks were the same as those of NH whites, 241,334 PYLLs and $3.2 billion lost earnings (22.6% of the total lost earnings among NH blacks) would have been avoided,” write the authors. “Improving equal access to effective cancer prevention, screening, and treatment will be important in reducing the disproportional economic burden associated with racial/ethnic disparities,” they conclude.


  • REPLAY: Special NCCRT webinar on the latest colorectal cancer stats and trends

    In this May 18 webinar, Robert Smith, PhD, senior vice president of cancer screening at ACS, and Rebecca Siegel, MPH, scientific director of surveillance research at ACS, provide a closer look at the findings from Colorectal Cancer Statistics 2020.

    Watch the replay here.

    The webinar focuses on findings released on March 5, 2020, that indicate the burden of colorectal cancer is swiftly shifting to younger individuals as incidence increases in young adults and declines in older age groups. 

    Also, the median age of diagnosis has dropped from age 72 in 2001-2002 to age 66 during 2015-2016, and half of all new diagnoses are in people 66 or younger. The publication is accompanied by a consumer version, Colorectal Cancer Facts & Figures and a press release is also available.


  • Advanced prostate cancer rates continued to rise after guideline change

    Rise accompanied by drop in early-stage cancers

    A new study led by ACS investigators finds rates of advanced prostate cancer continued to increase in men age 50 and over in the U.S., five years after the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen-based screening for all men. 

    The study says the rise in cancers that had spread beyond the prostate gland was accompanied by drops in early-stage disease during the same time period. The study appears in JNCI, the Journal of the National Cancer Institute.

    The researchers say future studies are needed to identify reasons for the rising trends.

    The USPSTF began recommending against prostate-specific antigen-based screening for men 75 and older in 2008, and for all men in 2012. In 2018, the USPTF recommended individual decision-making for men 55 to 69, and said men 70 and over should not be screened.

    National self-reported survey data found past-year routine PSA testing rates among men aged 50 and over declined from 40.6% in 2008 to 38.3% in 2010, to 31.5% in 2013, and remained unchanged in 2015.

    Previous studies reported that prostate cancer incidence rates in the U.S. declined for local-stage disease and increased for regional- and distant-stage disease soon after the USPSTF recommendations against routine screening. The new study looked at whether these patterns persisted in the longer-term, through 2016.

    Researchers led by Ahmedin Jemal, DVM, PhD (pictured here), used data from the U.S. Cancer Statistics Public Use Research Database to look at trends - annual percent change - in invasive prostate cancer incidence from 2005 to 2016 in men 50 and older stratified by stage, age group, and race/ethnicity.

    They found that for all races/ethnicities combined, incidence for local-stage disease decreased by 6.4% per year from 2007-2016 in men 50 to 74. In men 75 and older, incidence declined by 10.7% per year from 2007-2013 then stabilized during 2013 to 2016.

    In contrast, incidence for prostate cancer spread beyond the gland (regional- and distant-stage disease) increased in both age groups during the study period. For example, distant-stage incidence in men 75 and older increased by 5.2% per year from 2010-2016.

    "These data illustrate the trade-off between higher screening rates and more early-stage disease diagnoses (possibly overdiagnosis and overtreatment) and lower screening rates and more late-stage (possibly fatal) disease," write the authors. "Several modeling studies, however, showed that the harms associated with higher PSA screening rates can be mitigated while preserving the benefit of screening through PSA-stratified strategies including longer screening interval based on baseline PSA, higher PSA threshold for biopsy referral in older men, and restricting routine testing to men aged ≤70 years."

    The study did not cover the period after 2018, when USPTF recommendations changed again to include screening as an option for men 55 to 69, and against screening for men 70 and over. The impact of that most recent change on prostate cancer rates has yet to be seen, as cancer registry data is not yet available.


  • 16 of 19 new AACR fellows have ties to ACS

    ​We have a great track record of funding the best cancer research - here's more proof

    On May 12, the American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, whose mission is to recognize and honor distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer. 

    Fellows of the AACR Academy serve as a global brain trust in the cancer field, helping to advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

    We are pleased to report that of the 19 elected, 16 were either ACS grantees or mentors to ACS grantees. 

    They are: 

    • Myles A. Brown, MD - Emil Frei III Professor of Medicine; Director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston 
      For elucidating the role of steroid hormones and their receptors in promoting the onset and progression of various hormone-dependent malignancies and for the discovery of regulatory complex components such as the p160 class of transcriptional co-activators that facilitate the epigenetic regulation of steroid receptor activity. ACS grantee from 1992-1997; a former peer review committee member, and chair of the Council for Extramural Grants.

    • Judith Campisi, PhD - Professor, Buck Institute for Research on Aging, Novato, California; Senior Scientist, Lawrence Berkeley National Laboratory, Berkeley, California
      For groundbreaking contributions to the understanding of the links between aging and cancer and for her research related to identifying the molecular mechanisms associated with cellular senescence, aging, and tumorigenesis that has defined the role of DNA damage and repair in genomic instability and premature aging. ACS grantee from 1979-1981.

    • Arul Chinnaiyan, MD, PhD –Director, Michigan Center for Translational Pathology; S.P. Hicks Endowed Professor of Pathology; Professor of Urology; American Cancer Society Research Professor, University of Michigan, Ann Arbor
      For demonstrating the presence of chromosomal rearrangements in solid tumors including the identification of the TMPRSS2-ETS family of gene fusions and for harnessing such discoveries to define novel underlying pathologies in prostate cancer as well as other epithelial cancers. ACS grantee from 2002-2006 and 2009-2019. Named ACS Clinical Research Professor in 2009.

    • Alan D. D'Andrea, MD – Director, Susan F. Smith Center for Women's Cancers; Director of the Center for DNA Damage and Repair, Dana-Farber Cancer Institute; Alvan T. and Viola D. Fuller American Cancer Society Professor of Radiation Oncology, Harvard Medical School, Boston
      For pivotal contributions to the field of DNA damage and repair that have defined the specific defects responsible for the development of Fanconi anemia and for elucidating the role of nuclear protein complexes on chromatin remodeling, cell cycle checkpoints, and DNA repair. Primary mentor of two past ACS grantees.

    • Mark M. Davis, PhD – Director, Stanford Institute for Immunity, Transplantation and Infection; The Burt and Marion Avery Family Professor of Immunology, Stanford University School of Medicine, Stanford, California
      For identifying the first T cell receptor genes responsible for the detection of foreign antigens, contributing to the characterization of T cell receptor variable regions and for developing imaging techniques capable of capturing interactions that occur at immunological synapses. ACS grantee from 1984-1985 and primary mentor of three past ACS grantees.

    • Gregory J. Hannon, PhD - Director and Senior Group Leader, Cancer Research UK Cambridge Institute; Professor of Oncology, University of Cambridge, Cambridge, United Kingdom
      For fundamental contributions to characterizing the role of cyclin-dependent kinases and small RNAs including microRNAs, piwi-interacting, and short-hairpin RNAs in cell cycle regulation, carcinogenesis, and drug development. Primary mentor of two past ACS grantees.

    • Rakesh K. Jain, PhD – A. W. Cook Professor of Radiation Oncology (Tumor Biology); Director, E.L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston
      For landmark studies describing and highlighting the relationship between the tumor microenvironment and surrounding vasculature and for his investigations involving antiangiogenic therapy to induce tumor vascular normalization that have resulted in improved survival rates for a number of solid tumors. Five-time ACS grantee. First one in 1979; last one ended in 1996.

    • Maria Jasin, PhD – Laboratory Head, Memorial Sloan Kettering Cancer Center, New York
      For illuminating the role of homologous recombination in maintaining genetic stability, demonstrating the crucial role of BRCA1 and BRCA2 in facilitating such genetic events and for proving that BRCA2 loss, coupled with aberrant p53 activity in breast cells, can result in replication stress and subsequent tumorigenesis. ACS grantee from 1996-1999; primary mentor of four past ACS grantees.

    • Robert S. Langer, ScD - David H. Koch Institute Professor, Massachusetts Institute of Technology, Cambridge
      For vast contributions and discoveries in the field of drug delivery systems and for spearheading the fields of tissue engineering and regenerative medicine, generating synthetic polymer systems capable of facilitating controlled drug release as well as serving as platforms for the engineering of blood vessels, cartilage, and skin. Grantee from 1980-1982; primary mentor of two past ACS grantees.

    • Bert W. O'Malley, MD - Thomas C. Thompson Chair in Molecular and Cellular Biology; Chancellor, Baylor College of Medicine and Associate Director of Basic Research, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston
      For pioneering research focused on the understanding of molecular endocrinology, gene regulation, and steroid receptor biology that has revealed how intracellular hormones and cofactors function at the DNA level to regulate protein production, affect cellular function, and modulate cancer cell metastasis. ACS grantee from 1980-1987; primary mentor of three past ACS grantees.

    • Drew M. Pardoll, MD, PhD - Professor of Oncology; Director of Bloomberg~Kimmel Institute for Cancer Immunotherapy; Director of Cancer Immunology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore
      For enriching the understanding of tumor immunology and immunotherapy through his discovery of gamma-delta T cells and interferon-producing killer dendritic cells and for his contributions to developing GVAX and Listeria monocytogenes-based cancer vaccines. Primary mentor of three past ACS grantees.

    • Kornelia Polyak, MD, PhD – Professor of Medicine, Harvard Medical School; Dana-Farber Cancer Institute, Boston
      For dissecting the role of intratumor heterogeneity in breast cancer and metastatic disease to develop risk assessment and personalized cancer therapy models and for extensively characterizing the metastatic potential of polyclonal tumors compared to monoclonal tumors. ACS grantee from 2005-2009.

    • Peter J. Ratcliffe, FRS, FMedSci ­– Nuffield Professor of Clinical Medicine; Director, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford; Director of Clinical Research, Francis Crick Institute, London
      For his landmark, Nobel Prize-winning contributions to the understanding of the molecular responses to oxygen depletion, specifically the identification of oxygen sensing and signaling pathways that link hypoxia-inducible factor 1 to the availability of oxygen, which has proven to be critically important to the understanding of tumor initiation and progression. 

    • Antoni Ribas, MD, PhD – Professor of Medicine, Surgery and Molecular and Medical Pharmacology, University of California Los Angeles Medical Center, Los Angeles
      For his seminal clinical research contributions that have led to the development of pembrolizumab as the first-in-class approved anti-PD-1 immunotherapy for the treatment of melanoma, for his characterization of BRAF, CTLA-4, and MEK in cancer, and for deciphering the molecular mechanisms responsible for immunotherapeutic resistance, which have since fueled additional efforts to understand the relationship between the immune system and cancer.

    • Gregg L. Semenza, MD, PhD – Director, Vascular Program, Institute for Cell Engineering; C. Michael Armstrong Professor of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore 
      For his revolutionary, Nobel Prize-winning contributions to uncovering the molecular mechanisms of oxygen regulation within cells and for discovering hypoxia-inducible factor 1, critical for cellular adaptation to changing oxygen levels, which has had far-reaching implications for the treatment of numerous diseases characterized by low oxygen levels, including diabetes, heart disease, and cancer. ACS grantee from 2012 to the present; ACS Research Professor and 2019 Nobel Prize winner.

    • Charles Swanton, MD, PhD – Group Leader, The Francis Crick Institute and University College London Cancer Institute; Thoracic Oncologist University College London Hospitals, London
      For his innovative research focused on identifying molecular mechanisms of cancer evolution and its impact on drug resistance and patient stratification and for demonstrating the crucial biological connection between intratumor heterogeneity and clinical cancer biomarker efficacy. Primary mentor of two past ACS grantees.

    • David A. Tuveson, MD, PhD – Roy J. Zuckerberg Professor of Cancer Research; Director, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York
      For his trailblazing contributions to establishing human pancreatic cancer mouse models, for developing preclinical and clinical therapeutic strategies for the disease, and for characterizing many of the barriers to successful pancreatic cancer treatment, including poor drug delivery and the presence of survival factors in the microenvironment. Primary mentor of two past ACS grantees.

    • Michael Wigler, PhD – Russell and Janet Doubleday Professor of Cancer Research, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
      For his renowned contributions to cancer genetics and the establishment of genetically engineered animal cells and for first describing a role for the RAS gene family in human cancer and describing how point mutations are capable of activating the oncogenic potential of select genes. ACS grantee from 1984-2012; named ACS Research Professor in 1986; primary mentor of one past ACS grantee.
       
    • Sir Gregory P. Winter, CBE, FRS, FMedSci  Master, Trinity College; Professor Emeritus, Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom
      For Nobel Prize-winning scientific breakthroughs including the development of the first humanized antibodies, for establishment of refined phage display technology that has led to the development of adalimumab, the first marketed fully human antibody approved by the FDA, and for collective contributions to the generation of therapeutic antibodies for the treatment of various cancers and autoimmune diseases.

    All Fellows are nominated and elected through an annual peer review process conducted by existing Fellows of the AACR Academy and ratified by the AACR Academy Steering Committee and AACR Executive Committee. This process involves a rigorous assessment of each candidate’s scientific accomplishments in cancer research and cancer-related sciences. Only individuals whose work has had a significant and enduring impact on cancer research are considered for election and induction into the AACR Academy.

    About the American Association for Cancer Research

    Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 47,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. 

    The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 22,500 attendees. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. 

    The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit.


  • Climate change threatens progress in cancer control

    Commentary says climate change increases exposure to carcinogens and disrupts access to care

    Climate change threatens prospects for further progress in cancer prevention and control, increasing exposure to cancer risk factors and impacting access to cancer care, according to a new commentary by scientists from the American Cancer Society and Harvard T. H. Chan School of Public Health.

    The commentary, appearing in CA: A Cancer Journal for Clinicians, says that progress in the fight against cancer has been achieved through the identification and control of cancer risk factors and access to and receipt of care. And both these factors are impacted by climate change. Its authors are Leticia M. Nogueira, PhD, MPH and Robin Yabroff, PhD, both from our Surveillance and Health Services Research team; and Aaron Bernstein, MD, MPH, interim director of The Center for Climate, Health, and the Global Environment at the Harvard T.H. Chan School of Public Health (Harvard C-CHANGE), a pediatrician at Boston Children’s Hospital, and an assistant professor of pediatrics at Harvard Medical School.

    The authors say climate change creates conditions favorable to greater production of and exposure to known carcinogens. Climate change has been linked to an increase in extreme weather events, like hurricanes and wildfires, which can impact cancer. Hurricane Harvey for example inundated chemical plants, oil refineries, and Superfund sites that contained vast amounts of carcinogens that were released into the Houston community. Wildfires release immense amounts of air pollutants known to cause cancer. Both events can affect patients’ exposure to carcinogens and ability to seek preventive care and treatment, and they threaten the laboratory and clinic infrastructure dedicated to cancer care in the U.S.

    The authors propose ways to diminish the impact of climate change on cancer, because climate change mitigation efforts also have health benefits, especially to cancer prevention and outcomes. For example, air pollutants directly harmful to health are emitted by combustion processes that also contribute to greenhouse gas emissions. Some dietary patterns are also detrimental to both health and the environment. The agricultural sector contributes to approximately 30% of anthropogenic greenhouse gas emissions worldwide. Meat from ruminants have the highest environmental impact, while plant-based foods cause fewer adverse environmental effects per unit weight, per serving, per unit of energy, or per protein weight. Replacing animal source foods with plant-based foods, through guidelines provided to patients and changes made in the food services provided at cancer treatment facilities, would confer both environmental and health benefits.

    “While some may view these issues as beyond the scope of responsibility of the nation’s cancer treatment facilities, one need look no further than their mission statements, all of which speak to eradicating cancer,” write the authors. “Climate change and continued reliance on fossil fuels push that noble goal further from reach. However, if all those whose life work is to care for those with cancer made clear to the communities they serve that actions to combat climate change and lessen our use of fossil fuels could prevent cancers and improve cancer outcomes, we might see actions that address climate change flourish, and the attainment of our missions to reduce suffering from cancer grow nearer.”



  • Medal of Honor recipient Isaiah J. Fidler, DVM, PhD, dies at age 83

    ​He was a pioneer and leader in the study of cancer metastasis

    Isaiah J. Fidler, DVM, PhD, the 2013 recipient of the ACS Medal of Honor for Basic Research for his discoveries and contributions to the treatment of cancer metastasis, passed away May 8 at his home in Houston after a long illness. He was 83.

    A professor in cell biology and director of MD Anderson’s Metastasis Research Laboratory, Dr. Fidler was internationally renowned for exposing the origins of metastasis, the processes by which these cells spread and thrive in other organs, the molecular diversity that makes them so hard to treat, and the supporting role of their surrounding micro-environment. 

    Known to friends as Josh, Dr. Fidler came to MD Anderson in 1983, serving as the founding chair of Cancer Biology until 2008. He is a past president of the American Association for Cancer Research (AACR), and was inducted into the AACR Academy.  

    Dr. Fidler was born in Jerusalem on Dec. 4, 1936 to Shoshana Stern and Pinchas Fidler. His father, a world renown soccer player, died in Israel's war of independence in 1948. After attending school and serving in the Israeli army, Dr. Fidler came to America to study veterinary medicine.

    In 1963, Dr. Fidler earned his veterinary medicine degree from Oklahoma State University. He worked as a surgical oncologist at the University of Pennsylvania's School of Veterinary Medicine, and in 1970 he earned a doctoral degree in human pathology at the university's School of Medicine. His experience as a veterinary surgeon taught him that the deadliness of cancer is mainly due to the ability of cancer cells to spread, or metastasize, to other organs, so he devoted his career to the study of metastasis at a time when no one else was focusing on this topic.

     In 1975, Dr. Fidler joined the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), where he led the metastasis program at the Frederick Cancer Research Facility. His eight years there produced some of his early innovative work in unraveling the riddles of how cancer spreads.

    In 1983, Dr. Fidler joined The University of Texas MD Anderson Cancer Center as professor and founding chair of Cancer Biology, a department he led until 2008. Dr. Fidler held the R.E. "Bob' Smith Distinguished Chair in Cell Biology. For many more years, he continued his academic pursuits and leadership responsibilities, which included his role as director of MD Anderson's Cancer Metastasis Research Center and Metastasis Research Laboratory. In 2019, Dr. Fidler fully retired and was appointed the prestigious title of professor emeritus.

    Dr. Fidler's career of more than 50 years includes more than 820 publications in peer-reviewed journals. He oversaw numerous former trainees and mentees who now hold faculty leadership positions in research institutions around the world.


  • COVID-19 has halted work of half of ACS grantees

    We will delay the start date of our next round of grants from July 1, 2020 to September 1, 2020

    The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide its response to the COVID-19 pandemic. In early April 2020, we sent a survey to 744 current grantees via e-mail; 488 grantees responded, yielding a 66% response rate.

    In response to the question Are you currently working primarily from home or teleworking due to the COVID-19 pandemic? the survey found a high proportion of grantees are working remotely all or most of the time:

    • 54% were working entirely remotely
    • 32% were working mostly remotely with occasional in-person visits to office/campus/lab
    • 8% were working mostly or entirely in their normal work setting (6% in a clinical setting; 2% in a research setting)

    In response to the question: How has your institution responded to the pandemic?

    • 91% reported only essential personnel were allowed
    • 59% reported their institution had closed laboratories
    • 57% reported their institution had temporarily halted research
    • 4% reported their institution remained entirely open

    In response to the question What has been the impact on your research or training?

    • 51% indicate a high impact; all research or training activities are paused until further notice
    • 43% report a modest impact; some aspects are paused
    • 7% report a low impact; research or training continues as planned

    “It is abundantly clear that the COVID-19 pandemic is having a major impact on cancer research,” said William Phelps, PhD, senior vice president, Extramural Research. “In some labs queried for our survey, all non-essential research had been halted, with research on COVID-19 being the only type of research being encouraged. In addition to the deceleration in progress against cancer, these laboratories and institutions will face significant additional costs associated with restarting the cancer research enterprise in the coming months.”

    Despite the significant impact of closed laboratories, many researchers have found it a unique opportunity. Susanne Warner, MD, is an ACS grantee investigating the use of viruses to infect and destroy colorectal cancer cells at City of Hope in Duarte, California. “Despite being at home a lot more than usual, we've been able to be really productive in the lab,” said Dr. Warner. “We’re taking this opportunity to review a lot of our old data to see if there were messages that the science was trying to send us that we didn't have time to stop and listen to before. We’re also using the time to plan new experiments so that when all this is over, we can hit the ground running.”

    To accommodate the temporary closing of many research labs, the American Cancer Society will delay the start date of its next round of grants from July 1, 2020 to September 1, 2020.

    Read about COVID-19's possible effect on 2020 ACS grants.


  • Special NCCRT webinar on the latest colorectal cancer findings moved from May 11 to May 18; participants must re-register

    ​PLEASE NOTE: The date of this webinar has been moved from May 11 to May 18, 1 - 2 p.m. ET, to accommodate a new platform. Participants will need to re-register

    Robert Smith, PhD, senior vice president of cancer screening at ACS, and Rebecca Siegel, MPH, scientific director of surveillance research at ACS, will provide a closer look at the findings from Colorectal Cancer Statistics 2020 during a National Colorectal Cancer Roundtable (NCCRT) webinar on Monday, May 18, at 1 - 2 p.m. ET. 

    The webinar will focus on findings released on March 5, 2020, that indicate the burden of colorectal cancer is swiftly shifting to younger individuals as incidence increases in young adults and declines in older age groups. 

    Also, the median age of diagnosis has dropped from age 72 in 2001-2002 to age 66 during 2015-2016, and half of all new diagnoses are in people 66 or younger. The publication is accompanied by a consumer version, Colorectal Cancer Facts & Figures and a press release is also available.

    This webinar is open to NCCRT members, 80% Pledge partners, CDC grantees, ACS staff and volunteers, and other partners working to increase colorectal cancer screening rates. Registration is required and, as noted above, you will need to re-register if you registered for the previously scheduled date (May 11).


  • WATCH the replay of the virtual kickoff of the ResearcHERS 2020 fundraising campaign

    ​Hear highly successful women discuss how they maneuver in the male-dominated field of science

    The virtual launch of our 2020 ResearcHERS: Women Fighting Cancer program on Friday provided a fascinating look at the issues women confront in a field long dominated by men. They were very candid and offered some great advice for all women.

    Watch the replay here.

    Susanna Greer, PhD, scientific director at ACS and a host of our TheoryLab podcast, moderated the very impressive panel of women who shared why they are so committed to helping ACS fund some of the brightest minds in cancer research, who happen to be women. Their words were nothing short of inspirational.

    Dr. Greer began by sharing how important an ACS grant was to her when she ran a cancer lab. She also talked about the challenges of being a new mom and not having female models to emulate. "I really could have benefiting from something like ResearcHERS," she said, a support network for women in a very competitive and often isolating field of research.

    Panelists included Pamela Kreeger, PhD, associate professor of biomedical engineering at the University of Wisconsin-Madison and an ACS-funded researcher; Debra Patt, MD, executive vice president at Texas Oncology; and Connie L. Lindsey, executive vice president and head of corporate social responsibility and global diversity, equity, and inclusion at Northern Trust, Chicago. Connie provided the additional perspective of barriers faced by people of color, and the importance of girls having role models. The former national president of Girl Scouts USA said: "Young girls can't be what they can't see," and she said it's critical that careers in science not be limited to those who can afford it. 

    The launch kicked off a month-long effort by ResearcHERS Ambassadors to raise a minimum of $2,500 each to support women-led research. Approximately 900 individuals have signed up to be Ambassadors for the program.

    Ambassadors will receive an email with a special video message from Alpa Patel, PhD, senior scientific director for epidemiology research at ACS. They will be encouraged to set up their Facebook fundraiser, email their personal network, and amplify the need for funds on LinkedIn.

    ResearcHERS was a regional pilot in 2019 patterned after Real Men Wear Pink. The 2020 goal is to raise $3 million in revenue to fund women-led research grants. It is not too late to share this information with influencers who might be interested in signing on as ambassadors. For more information, visit the ResearcHERS channel on You Tube. 

    TOP PHOTO: Clockwise from far left: Susanna Greer, PhD; Connie Lindsey' Debra Patt, MD; and Pamela Kreeger, PhD.


back to top